(NOTV) Inotiv - Ratings and Ratios

Inotiv, Inc. (NASDAQ:NOTV) is a life sciences company specializing in nonclinical and analytical drug discovery and development services for pharmaceutical and medical device industries. The company operates through two primary segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment focuses on providing comprehensive toxicology, safety assessment, and analytical services to support drug development. The RMS segment offers research models, diets, bedding, and bioproducts for preclinical research. In addition, the company manufactures scientific instruments and related software under its BASi product line, catering to pharmaceutical companies, universities, and research institutions. Inotiv, Inc. was formerly known as Bioanalytical Systems, Inc. and rebranded in March 2021. Headquartered in West Lafayette, Indiana, the company has been operational since its incorporation in 1974. Web URL: https://www.inotiv.com

As of the latest data, Inotiv, Inc. has a market capitalization of approximately $117.19 million. The stock is categorized under the Life Sciences Tools & Services industry and is listed on the NASDAQ exchange under the ticker symbol NOTV. The companys financial metrics indicate a price-to-book ratio of 0.76 and a price-to-sales ratio of 0.25, suggesting a potentially undervalued stock. However, the return on equity stands at -71.06%, reflecting significant profitability challenges. The stocks average 20-day volume is 801,941 shares, with a last price of $2.78. The short-term technical outlook is bearish, as the stock price is below its 20-day and 50-day simple moving averages of $3.75 and $4.15, respectively. The 200-day simple moving average is $2.64, indicating long-term support near current levels. The average true range (ATR) of 0.45 suggests moderate volatility.